Vistagen, jittery after seeing rivals fail, pauses plan to restart phase 3 anxiety trial pending FDA talks

Failed clinical trials have put Vistagen on edge. After seeing two rival social anxiety disorder candidates flunk phase 2 studies, the biotech has paused plans to resume a phase 3 trial of its own once-failed prospect PH94B pending talks with the FDA.